China Healthcare Select

On May 26, 2025, Gan&Lee Pharmaceuticals (603087.SH) announced it has received Good Manufacturing Practice (GMP) certification from Brazil’s National Health Surveillance Agency (ANVISA) for its Insulin Aspart and Insulin Lispro formulations, following April 2025 API certifications for the same products. This dual compliance—covering both active pharmaceutical ingredients and finished formulations—for Insulin Glargine, Insulin Lispro, and Insulin Aspart confirms the company’s full alignment with Brazilian regulatory standards. With 16.62 million diabetes patients in Brazil and healthcare spending ranked third globally, this milestone positions Gan&Lee to launch its proprietary insulin brands in a market historically dominated by Eli Lilly, Novo Nordisk, and Sanofi.

STAR Market-listed Chinese biopharmaceutical companies are showcasing a record-breaking presence at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, with 95 abstracts led by Chinese scholars—nearly doubling since 2024—and 12 selected as Late-Breaking Abstracts (LBA). Two pivotal LBA oral presentations highlight breakthrough therapies: Dizal’s sunvozertinib (EGFR TKI) in EGFR exon20ins NSCLC and Biokin’s iza-bren (first-in-class bispecific ADC) in triple-negative breast cancer, both meeting primary endpoints with significant PFS and OS benefits. Additional innovations span immunotherapy, small molecules, ADCs, and multi-specific antibodies from companies including BeOne Medicines, InnoCare Pharma, Bio-Thera, RemeGen, and ZeGen. This surge underscores China’s transition from participant to global leader in oncology innovation, driven by high-quality clinical evidence and strategic capital market support.

Junshi Biosciences announced that its Phase III NEOTORCH study of toripalimab, an anti-PD-1 monoclonal antibody, combined with platinum-doublet chemotherapy as perioperative treatment for resectable Stage II-III non-small cell lung cancer (NSCLC), has achieved all three primary endpoints: event-free survival (EFS) and major pathological response (MPR) rates in both Stage II-III and Stage III populations. The company plans to submit a supplemental regulatory application to expand the approved indication from Stage III to Stage II-III resectable NSCLC.

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SSE: 600276.SH) announced that its subsidiary Suzhou Suncadia Biopharmaceuticals Co., Ltd. has received a Clinical Trial Approval Notice from China's National Medical Products Administration (NMPA) for SHR-5421 for Injection, an innovative anti-tumor drug developed in-house for the treatment of multiple myeloma. No comparable therapy has been approved globally to date. The project has incurred approximately RMB 20.3 million in cumulative R&D expenditures (unaudited). Clinical trials are set to commence shortly, marking a key advancement in Hengrui’s oncology pipeline.

Hengrui Pharma announced that its subsidiary Suzhou Suncadia Biopharmaceuticals has received NMPA approval to initiate clinical trials for SHR-5421 for Injection, an innovative anti-tumor drug developed in-house for the treatment of multiple myeloma. No similar drug has been approved globally to date, making SHR-5421 a potential first-in-class therapy. Cumulative R&D investment in the project amounts to approximately CNY 20.3 million (unaudited). Clinical trials are expected to commence shortly.

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (600276.SH) announced that its subsidiary Chengdu Shengdi Pharmaceutical has received a Clinical Trial Approval Notice from China's National Medical Products Administration (NMPA) for HRS-1635 tablets, an innovative anti-tumor drug developed in-house for the treatment of B-cell malignancies. No comparable drug has been approved globally to date, indicating first-in-class potential. The company has invested approximately ¥23.6 million (unaudited) in the project and plans to initiate clinical trials shortly.